Product description Brand name COMIRNATY that has been approved recently by Health Canada Company name BioNTech Manufacturing GmbH Ingredient mRNA encoding SARS-CoV-2 spike protein, 5’ [m27,3’-OGppp(m12’-O)ApG] cap, 110-nucleotide 3′ poly(A) tail with a 10-nucleotide linker sequence. This product (COMIRNATY) includes an update to the antigen composition (variant Omicron KP.2) and replaces COMIRNATY Omicron XBB.1.5 (raxtozinameran).
All about antigen composition of Covid-19 vaccines
Geneva -The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) continues to meet regularly to assess the implications of SARS-CoV-2 evolution for COVID-19 vaccine antigen composition and advise WHO on whether changes are needed to the antigen composition of future COVID-19 vaccines. In April 2023, the TAG-CO-VAC indicated that the advisory group would convene at least twice in 2023: once in …